BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Proesmans M. Best practices in the treatment of early cystic fibrosis lung disease. Ther Adv Respir Dis 2017;11:97-104. [PMID: 27913761 DOI: 10.1177/1753465816680573] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Hamed K, Debonnett L. Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence. Ther Adv Respir Dis 2017;11:193-209. [PMID: 28470103 DOI: 10.1177/1753465817691239] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
2 Thorat T, McGarry LJ, Bonafede MM, Limone BL, Rubin JL, Jariwala-Parikh K, Konstan MW. Healthcare resource utilization and costs among children with cystic fibrosis in the United States. Pediatr Pulmonol 2021;56:2833-44. [PMID: 34138523 DOI: 10.1002/ppul.25535] [Reference Citation Analysis]
3 Joyce S, Carey BW, Moore N, Mullane D, Moore M, McEntee MF, Plant BJ, Maher MM, O'Connor OJ. Computed tomography in cystic fibrosis lung disease: a focus on radiation exposure. Pediatr Radiol 2021;51:544-53. [PMID: 33743038 DOI: 10.1007/s00247-020-04706-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Colombo C, Nobili RM, Alicandro G. Challenges with optimizing nutrition in cystic fibrosis. Expert Rev Respir Med 2019;13:533-44. [PMID: 31094240 DOI: 10.1080/17476348.2019.1614917] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]